Table 3.
Baseline Clinical Characteristics for Patients With RR-NSVT With Appropriate ICD Shocks Versus Those With RR-NSVT Without Appropriate ICD Shocks
| Baseline Characteristic | RR-NSVT With APP (n = 86) |
RR-NSVT Without APP (n = 100) |
p Value* |
|---|---|---|---|
| Age (yrs) | 63 (51, 69) | 56 (48, 65) | 0.018 |
| Women | 15% (13) | 18% (18) | 0.60 |
| Nonwhite race | 23% (20) | 31% (31) | 0.24 |
| Weight (lb) | 192 (160, 221) | 193 (167, 227) | 0.55 |
| NYHA functional class III | 41% (35) | 31% (31) | 0.17 |
| Ischemic HF etiology | 47% (40) | 34% (34) | 0.082 |
| Ejection fraction (%) | 20 (18, 25) | 22 (16, 30) | 0.41 |
| Diabetes | 20% (17) | 25% (25) | 0.39 |
| Pulmonary disease | 24% (21) | 19% (19) | 0.37 |
| Hyperlipidemia | 43% (37) | 41% (41) | 0.78 |
| Hypertension | 51% (44) | 60% (60) | 0.23 |
| Atrial fibrillation/flutter | 19% (16) | 17% (17) | 0.78 |
| NSVT (before enrollment) | 38% (33) | 29% (29) | 0.18 |
| Syncope | 10% (9) | 6% (6) | 0.27 |
| QRS duration ≥120 ms | 43% (37) | 40% (40) | 0.68 |
| Systolic blood pressure (mm Hg) | 120 (108, 132) | 115 (106, 131) | 0.38 |
| Diastolic blood pressure (mm Hg) | 70 (63, 80) | 70 (61, 79) | 0.46 |
| Heart rate (beats/min) | 76 (68, 88) | 76 (68, 88) | 0.99 |
| Serum sodium (mEq/l) | 139 (137, 141) | 139 (137, 141) | 0.91 |
| Serum creatinine (mg/dl) | 1.10 (0.96, 1.30) | 1.10 (0.90, 1.30) | 0.84 |
| ACE inhibitors or ARBs | 97% (83) | 99% (99) | 0.24 |
| Beta-blocker | 51% (44) | 66% (66) | 0.040 |
| Digoxin | 76% (65) | 68% (68) | 0.25 |
| Aspirin | 53% (46) | 49% (49) | 0.54 |
| Statins | 26% (22) | 27% (27) | 0.83 |
| Aldosterone antagonist | 10% (9) | 18% (18) | 0.14 |
Values are median (25th, 75th percentile) or % (n).
*
Likelihood ratio chi-square tests for categorical variables and Wilcoxon rank sum tests for continuous variables.
APP = appropriate ICD shock for ventricular tachycardia or ventricular fibrillation; ICD = implantable cardiac defibrillator; NSVT = nonsustained ventricular tachycardia. Other abbreviations as in Table 2.